The Prestige LP cervical disc is the first FDA approved one- and two-level cervical disc with 10 year IDE study data.VIEW Clinical DATA
Discover features and benefits of the Prestige LP cervical disc system (2:29).
Risk includes wear debris.
The titanium carbide is NOT a coating on the implant. It is a component of the material mixture.
A CT myelogram may be required for adequate visualization; MR conditional at 1.5 and 3 Tesla.
Risks include loss of motion.
Watch how Prestige works (3:10).
Gornet, et al. (2019)2 conducted a prospective, prospective, randomized, controlled, multicenter FDA-approved clinical trial, assessing the 10-year clinical safety and effectiveness of cervical arthroplasty compared to anterior cervical discectomy and fusion (ACDF). The clinical trial involved 397 patients (209 patients who received the Prestige LP Cervical Disc at two adjacent levels and 188 patients who underwent a fusion procedure, ACDF, at two adjacent levels).
Through two years after surgery, 5 out of 209 patients (2.4%) treated with the Prestige LP Cervical Disc at two adjacent levels and 15 out of 188 patients (8.5%) treated with ACDF at two adjacent levels had additional surgery at the same levels. In addition, 5 out of 209 patients (2.4%) treated with the Prestige LP Cervical Disc at two adjacent levels and 6 out of 188 patients (3.4%) treated with ACDF at two adjacent levels had additional surgery at a level adjacent to the levels originally treated.
Through ten years after surgery, 9 out of 209 patients (4.7%) treated with the Prestige LP Cervical Disc at two adjacent levels and 27 out of 188 patients (17.6%) treated with ACDF at two adjacent levels had additional surgery at the same levels. In addition, 16 out of 209 patients (9.0%) treated with the Prestige LP Cervical Disc at two adjacent levels and 24 out of 188 patients (7.9%) treated with ACDF at two adjacent levels had additional surgery at a level adjacent to the levels originally treated.
Risks of the PRESTIGE LP Cervical Disc include, but are not limited to:
As compared to original Prestige LP Instruments (2014).
Not necessarily indicative of clinical results.
CT Myelogram may be required for adequate visualization; MR conditional at 1.5 or 4 Tesla.
Pin distraction optional.
Gornet et al. Cervical disc arthroplasty: 10-year outcomes of the Prestige LP cervical disc at a single level. J Neurosurg Spine, 2019.
Matthew F. Gornet et al. Two-level cervical arthroplasty versus anterior cervical discectomy and fusion: 10-year outcomes of a prospective, randomized investigational device exemption clinical trial. J Neurosurg Spine. June 2019.
Based on mechanical testing according to ISO (18192-1) and ASTM (F2423-05).
Gornet et al. Serum Metal Concentrations in Patients With Titanium Ceramic Composite Cervical Disc Replacements. SPINE. Vol 42. Number 6, pp. 336 – 371.
Sekhon et. al. Magnetic Resonance Imaging Clarity of the Bryan, Prodisc-C, Prestige LP and PCM Cervical Arthroplasty Devices. SPINE. Volume 32, Number 6, pp 673– 680, 2007.
BRIEF SUMMARY OF INDICATIONS, CONTRAINDICATIONS, AND WARNINGS FOR THE PRESTIGE LP CERVICAL DISC:
The PRESTIGE LP Cervical Disc is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following discectomy at one level or two contiguous levels for intractable radiculopathy (arm pain and/or a neurological deficit) with or without neck pain, or myelopathy due to abnormality localized to the level of the disc space and at least one of the following conditions confirmed by imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels. The PRESTIGE LP Cervical Disc is implanted using an anterior approach. Patients should have failed at least 6 weeks of non-operative treatment or have had the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management prior to implantation of the PRESTIGE LP Cervical Disc.
The PRESTIGE LP Cervical Disc should not be implanted in patients with active systemic infection or localized infection at the surgical site; osteoporosis or osteopenia defined as a DEXA bone mineral density T-score ≤ -1.0; allergy or sensitivity to titanium, aluminum or vanadium; marked cervical instability on neutral resting lateral or flexion/extension radiographs; translation >3.5mm and/or >11° rotational difference from that of either level adjacent to the treated levels; severe spondylosis at the level to be treated, characterized by bridging osteophytes, loss of disc height >50%, an absence of motion (<2°) as this may lead to a limited range of motion and may encourage bone formation (e.g. heterotopic ossification, fusion); severe facet joint arthropathy; significant cervical anatomical deformity or clinically compromised vertebral bodies at the affected level(s) due to current or past trauma (e.g., by radiographic appearance of fracture callus, malunion or nonunion) or disease (e.g., ankylosing spondylitis, rheumatoid arthritis); or significant kyphotic deformity or significant reversal of lordosis.
The PRESTIGE LP Cervical Disc should only be used by surgeons who are experienced with anterior cervical spinal procedures and have undergone adequate hands-on training in the use of this specific device. Only surgeons who are familiar with the implant components, instruments, procedure, clinical applications, biomechanics, adverse events, and risks associated with the PRESTIGE LP Cervical Disc should use this device. Medtronic will offer hands-on training to physicians prior to their first use of the device. A lack of adequate experience and/or training may lead to a higher incidence of adverse events, including neurological complications.
The safety and effectiveness of this device has not been established in patients with the following conditions: axial neck pain as the solitary symptom; skeletally immature patients, pediatric or adolescent children (<21 years old), or those over the age of 78; prior cervical spine surgery, including prior surgery at the index level or adjacent levels; more than two cervical discs or two non-adjacent cervical discs that require surgical treatment; facet joint pathology of involved vertebral bodies; spinal metastases; an endocrine or metabolic disease that affects bones such as Paget’s disease, osteomalacia, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta; chronic or acute renal failure or history of renal disease; taking medications known to potentially interfere with bone/soft tissue healing (e.g., steroids); diabetes mellitus requiring daily insulin management; serious mental illness; being treated for alcohol and/or drug abuse; and pregnant.
Devices with metal-on-metal articulating surfaces (such as the Prestige LP Cervical Disc) may release wear debris, metallic particles or metal ions locally near the device and/or systemically. The short and long term effects of the wear debris, metallic particles and metal ions on the body are not known, but certain groups of patients may be at a higher risk including patients who are pregnant, patients who are planning to get pregnant, and patients who have renal disease.
Patients in the clinical study of the PRESTIGE LP Cervical Disc were instructed to use non-steroidal anti-inflammatory drugs (NSAIDs) for two weeks postoperatively. It has been reported in the literature that short-term postoperative use of NSAIDs may reduce the instance of heterotopic ossification (HO). To reduce the instance of HO, it is recommended that the PRESTIGE LP device be implanted in subjects able to tolerate the use of NSAIDs for two weeks post-operatively.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
Please see the package insert for the complete list of indications, warnings, precautions, adverse events, clinical results, and other important medical information.